
"We have promising clinical data and a team that has done it before. RTP-026 demonstrated a strong safety and tolerability profile, alongside encouraging efficacy signals in Phase 2a. Our team has previously developed drugs and closed major international pharma deals."
CEO Anders Kronborg, Resother Pharma
For those not yet familiar with ResoTher Pharma, could you briefly describe the company, your business model, and how you position yourselves within your market?
ResoTher Pharma is a Danish clinical-stage biotech company founded a little less than ten years ago. We develop resolution therapeutics – a new class of drugs that helps the body’s immune system actively switch off harmful inflammation and repair damaged tissue. This novel approach to treating dangerous hyperinflammation has a number of advantages over current anti-inflammatory treatments which works by generally suppressing the entire immune system. We own all rights to the underlying patented invention from the William Harvey Research Institute at Queen Mary University of London, and we are among the most advanced clinical companies in this field globally.
We focus on providing better treatment options for acute serious hyperinflammatory diseases which require hospital treatment and affect millions or patients each year. Our lead candidate, RTP-026, has just completed Phase 2a and is now moving into Phase 2b to treat serious complications after a severe heart attack. Our business model is not to take the drug all the way to market ourselves. The aim is to generate proof-of-efficacy in Phase 2b and thereafter enter into a licensing or partnership deal with a large international pharmaceutical company – or sell RTP-026 or the company. This is a route our team knows well: our founders were behind Action Pharma, where a Phase 2b programme was sold to Abbott for USD 110 million, and board member Henrik Stage was CEO of Santaris Pharma, which was sold to Roche in a deal worth up to USD 450 million.
Severe heart attack is our first indication, but resolution therapy has demonstrated relevance and attractive potential across many other acute hyperinflammatory diseases.
You are developing RTP-026 as a potential treatment to protect the heart after a severe heart attack. Could you explain the unmet medical need you are addressing, and what makes your approach different?
When a patient suffers a severe heart attack – also referred to as an ST-elevation myocardial infarction or STEMI, where a coronary artery is completely blocked – the standard treatment is to reopen the artery as quickly as possible with a balloon procedure to restore blood flow and oxygen supply to the heart. That saves lives. But when blood flow returns to a diseased heart region, it can trigger a powerful inflammatory reaction, which causes further damage to the heart muscle. This has severe consequences for patients including reduced heart function, higher risk of heart failure, , new heart attacks and shorter life expectancy.
Today there is no approved treatment that specifically targets this chronic inflammation-driven damage. Between 4.5 and 6 million people suffer a STEMI every year worldwide, so the medical need is both large and well known.
RTP-026 is a unique approach, in that it mimics a protein the body produces itself and which plays an essential role to brake the inflammatory responseand help the body heal itself without weakening the immune system. In animal models, RTP-026 was able to reduce post-refusion damage to the heart muscle by up to 50 percent and restore the heart’s pumping function. We are very encouraged that we have now seen supporting signals of the same effect in patients from our Phase 2a study.
In September, you announced topline results from a Phase IIa study of RTP-026. How do you view these findings, and what do they mean for the next step in development?
We are very pleased with them. Our randomised, double-blind, placebo-controlled study included 66 high-risk STEMI patients and was primarily designed to assess safety and tolerability. Considering the limited number of patients in the study, we did not expect to see much in terms of efficacy.
Despite this, we saw several encouraging efficacy signals. These included a median improvement in left ventricular ejection fraction – a key measure of how well the heart pumps – after 90 days of8 percentage points in both treatment groups, compared with 2.5 percentage points in the placebo group. We also saw supporting signals indicating a reduction in infarct size after treatment with RTP-026. Already in June, based on blinded data, we could see that safety and tolerability were excellent, in line with our expectations.
The promising findings of the Phase 2a study, gives us a solid basis for designing a Phase 2b study, for which we are currently finalising the protocol.
The next major step is a larger international Phase IIb trial. Could you walk us through the planned study design and the key steps ahead?
We expect to submit the clinical trial application for the Phase 2b study at the end of 2026. Pending approval we expect to include the first patient around April 2027. The study is planned to include more than 200 patients across several European countries and will be run by Medpace, one of the world’s leading contract research organisations, with extensive experience in running cardiovascular trials. The objective of the study is to demonstrate that RTP-026 improves heart function in STEMI patients after a ballon procedure with the potential to improve clinical outcomes and long-term survival.
We expect all patients to be enrolled by the end of 2027 and to have top-line results in the third quarter of 2028.
Positive Phase 2b data would be the decisive value driver for the company. An independent analysis from Xplico estimates a potential M&A value for RTP-026 of EUR 569 million – around SEK 6.3 billion – on positive Phase 2b results, based on an addressable market of around 155,000 patients and potential annual sales of almost EUR 1 billion. Recent deals show that big pharma is willing to pay for this kind of asset: Eli Lilly announced the acquisition of Ventyx Biosciences for around USD 1.2 billion this year, and Novo Nordisk acquired both Corvidia Therapeutics and Cardior Pharmaceuticals – both in Phase 2 within cardiovascular disease – in deals worth up to USD 2.1 billion and EUR 1.025 billion respectively.
You are preparing to list on Spotlight through a reverse acquisition by Hunter Capital RTO 1, subject to the necessary approvals. Why did you choose this route rather than a traditional IPO, and how do you view the financing connected to the transaction?
The two questions are closely linked. For us, the reverse takeover represents a direct route to both immediate funding and the stock market. This is particularly valuable at a time where the IPO window for non-validated biotech companies is closed and new risk-willing funding extremely scarce
In our case, the financing has been arranged ahead of the transaction, amounting in total to SEK 80 million and giving us a clear financial foundation as we prepare for the next phase of clinical development.
We raised SEK 15 million in May this year to fund the start-up of preparations for Phase 2b and SEK approximately SEK 65 million in further financing will be available in connection with the listing. This is expected to fund our activities into 2028unti, when all patients in the Phase 2b study are expected to be enrolled.
The option of listing via a reverse acquisition by an already listed company is not new, however in our case the merger will be with a clean empty company with no negative legacy and a solid shareholder base.
Looking ahead, where do you see ResoTher Pharma one year from now?
One year from now, we expect to be a listed company running an international Phase 2b study with a potential first-in-class drug targeting a high medical need, with patient recruitment well under way to build certainty for study completion and readout in the third quarter of 2028. In parallel, we will continue our dialogue with potential pharma partners and look at how resolution therapy can be used in other acute hyperinflammatory diseases.
Finally, can you give three reasons why ResoTher Pharma is an interesting investment case at this stage?
First, a large unmet medical need with significant commercial potential. Millions of people suffer a severe heart attack every year, and there is no approved treatment for the inflammatory damage that follows. An independent analysis estimates potential annual sales of almost EUR 1 billion.
Second, promising clinical data and a team that has done it before. RTP-026 demonstrated a strong safety and tolerability profile, alongside encouraging efficacy signals in Phase 2a. And our team has previously developed drugs and closed major international pharma deals.
Third, a clear, near-term value driver. We are funded until all patients are enrolled in Phase 2b, and the data are expected in less than two years. The listed company is valued at around SEK 333 million, while the independent analysis estimates a potential M&A value of around SEK 6.3 billion on positive Phase 2b results. That is the very attractive value potential investors have the opportunity to be part of.
